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Abstract——Chemerin, a chemoattractant protein
and adipokine, has been identified as the endogenous
ligand for a G protein–coupled receptor encoded by the
gene CMKLR1 (also known as ChemR23), and as a
consequence the receptor protein was renamed the
chemerin receptor in 2013. Since then, chemerin has
been identified as the endogenous ligand for a second G
protein–coupled receptor, encoded by the gene GPR1.
Therefore, the International Union of Basic and Clinical
Pharmacology Committee on Receptor Nomenclature
and Drug Classification recommends that the official
name of the receptor protein for chemokine-like
receptor 1 (CMKLR1) is chemerin receptor 1, and G
protein–coupled receptor 1 is chemerin receptor 2 to
follow the convention of naming the receptor protein
after the endogenous ligand. Chemerin receptor 1 and
chemerin receptor 2 can be abbreviated to Chemerin1
and Chemerin2, respectively. Chemerin requires
C-terminal processing for activity, and human
chemerin21–157 is reported to be the most active
form, with peptide fragments derived from the C
terminus biologically active at both receptors. Small-
molecule antagonist, CCX832, selectively blocks
CMKLR1, and resolvin E1 activation of CMKLR1 is
discussed. Activation of both receptors by chemerin is
via coupling to Gi/o, causing inhibition of adenylyl
cyclase and increased Ca2+ flux. Receptors and ligand
are widely expressed in humans, rats, and mice, and
both receptors share∼80% identity across these species.
CMKLR1 knockout mice highlight the role of this
receptor in inflammation and obesity, and similarly,
GPR1 knockout mice exhibit glucose intolerance. In
addition, the chemerin receptors have been implicated
in cardiovascular disease, cancer, steroidogenesis,
human immunodeficiency virus replication, and
neurogenerative disease.
I. Introduction
Chemerin, the endogenous ligand of chemokine-like
receptor 1 (CMKLR1) or ChemR23, was identified in
2003 as the product of the RARRES2 gene (Meder et al.,
2003; Wittamer et al., 2003). In 1997, the RARRES2 gene
was first identified as a novel retinoid-responsive gene in
psoriatic skin lesions (Nagpal et al., 1997). As a conse-
quence of its production in response to retinoid substances,
the gene product was initially christened as tazarotene-
induced gene 2 (TIG2) or retinoic acid receptor responder
2 protein (RARRES2). The human gene translates into a
163-amino-acid protein (mol. wt. 18,618 Da), made up of a
20-amino-acid hydrophobic N-terminal signal peptide, an
intervening 137-amino-acid cystatin-fold containing
domain, and a six-amino-acid C-terminal prosegment
(Fig. 1A). Amino acids 21–157, corresponding to the
137-amino-acid intervening region, were found to be the
active part of the protein and subsequently named chem-
erin (Wittamer et al., 2003). Prochemerin, the 143-amino-
acidprecursorprotein (21–163), released following cleavage
of the signal peptide, circulates in the plasma and has low
biologic activity; it needs to be further processed at the C
terminus to give the active form (Meder et al., 2003;
Wittamer et al., 2003; Zabel et al., 2005a,b; Cash et al.,
2008; Du et al., 2009; Ernst and Sinal, 2010).More detailed
reviews are listed in Table 1. Human chemerin21–157 is
reported to be the most active form; removal of one amino
acid (chemerin21–156) resulted in a sixfold drop in potency,
whereas the addition of one or removal of two or three
amino acids strongly affected potency, with no response
seen up to 10mM(Wittamer et al., 2004). TheC terminus is
therefore very important for function at CMKLR1, exem-
plified further by synthetic C-terminal fragments of human
chemerin: C9 (or chemerin-9), chemerin149–157; C13,
chemerin145–157 (Wittamer et al., 2004); and C20, chem-
erin138–157 (Li et al., 2014a), possessing biologic activity
(Fig. 1C). It is not yet known whether these short peptides
are generated endogenously.
In addition to activating CMKLR1, human chem-
erin21–157, C9, and C13 have also been found to
ABBREVIATIONS: Ab42, amyloid-b peptide 42; CHO, Chinese hamster ovary; CMKLR1, chemokine-like receptor 1; GPCR, G protein–
coupled receptor; GPR1, G protein–coupled receptor 1; HIV, human immunodeficiency virus; MAPK, mitogen-activated protein kinase;
a-NETA, 2-(anaphthoyl) ethyltrimethylammonium iodide; PTX, pertussis toxin; RvE1, resolvin E1; SNP, single nucleotide polymorphism;
TNF, tumor necrosis factor; WT, wild-type.
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activate orphan receptor, G protein–coupled receptor
1 (GPR1). This pairing was initially discovered due to
the high sequence identity between GPR1 and
CMKLR1 (Barnea et al., 2008) and has subsequently
been independently confirmed (Southern et al., 2013;
Rourke et al., 2014; Kennedy et al., 2016).
Chemerin has also been shown to bind to chemokine
(C-C motif) receptor-like 2, but it does not activate any
downstream signaling pathways or internalization
(Zabel et al., 2008). Chemokine (C-C motif) receptor-
like 2 is therefore designated an atypical chemokine
receptor (Bachelerie et al., 2015) and is not covered
in this review of signaling receptors. For more
information, please see the review by Yoshimura and
Oppenheim (2011).
The initial interest in the chemerin system was
focused on its role in inflammation and chemotaxis of
immune cells following its discovery in psoriasis. How-
ever, in 2007, there was a fundamental shift in the
understanding of chemerin biology when its function as
an adipokine was identified. More recently, in connec-
tion with its roles in inflammation, obesity, and meta-
bolic syndrome, a potential role in the cardiovascular
system is being considered, as well as roles in repro-
ductive biology. This review will focus on the pharma-
cology of the signaling chemerin receptors; for more
detailed information on function, the reviews listed in
Table 1 should be consulted.
In accordancewith the standard InternationalUnion of
Basic and Clinical Pharmacology Committee on Receptor
Fig. 1. Agonists and antagonists of the chemerin receptors. (A) The 163-amino-acid sequence of chemerin (Uniprot: Q99969). The signal peptide is
underlined; the cysteine residues involved in three disulfide bonds are marked ^, “, and ‘ in pairs. The residues marked with * were found to be
important for binding to chemerin receptor 1 by alanine screening. (B) Amino acids corresponding to C9, C13, C15, and C20 synthetic peptides that
activate downstream signalling at CMKLR1 and GPR1. Chemspider structures of (C) CMKLR1 agonist RvE1 and (D) CMKLR1 antagonist, a-NETO.
NB. The structure of CCX832 is not publicly available.
TABLE 1
Detailed reviews
Focus of the review Reference
Chemerin activation Zabel et al., 2006; Ernst and Sinal, 2010; Mattern et al., 2014
Chemerin receptors Yoshimura and Oppenheim, 2011
Function of chemerin Mattern et al., 2014; Ferland and Watts, 2015; Mariani
and Roncucci, 2015; Fatima et al., 2014; Zabel et al.,
2014; Bondue et al., 2011b
General overview Ernst and Sinal, 2010; Fatima et al., 2014; Mattern et al., 2014
Inflammation Zabel et al., 2014; Mariani and Roncucci, 2015
Obesity Roman et al., 2012
Cardiovascular disease Ferland and Watts, 2015
Cancer Mariani and Roncucci, 2015
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Nomenclature and Drug Classification (NC-IUPHAR)
rules of nomenclature, which state that a receptor is
named after its endogenous agonist (Vanhoutte et al.,
1996), the CMKLR1 receptor was renamed the chem-
erin receptor in 2013 (Davenport et al., 2013). Following
the identification of GPR1 as a second signaling chem-
erin receptor, we therefore propose that, at the protein
level, CMKLR1 is referred to as chemerin receptor 1 and
GPR1 is referred to as chemerin receptor 2. We also
suggest abbreviating chemerin receptor 1 and chemerin
receptor 2 to Chemerin1 and Chemerin2, respectively.
When referring to chemerin as an agonist for these
receptors, it is imperative to state the number of the
corresponding amino acids and which species chemerin
is derived from, for example, human chemerin21–157,
in which the first number represents the first amino
acid from the 163-amino-acid prochemerin sequence,
and the second number represents the last. Note the
numbering of amino acids in the mouse sequence
corresponding to the same amino acid of the human
sequence differs by one due to themouse sequence being
one amino acid shorter. Smaller fragments, such as C9,
C13, and C20, can be abbreviated, but for clarity it is
still necessary to state the species and corresponding
residues on first use. Names of genes should be
italicized and, consistent with the Human Genome
Organization, CMKLR1 refers to chemerin receptor 1,
GPR1 refers to chemerin receptor 2, and RARRES2
refers to chemerin, with lower case letters used for
nonhuman species (Table 2).
II. Chemokine-Like Receptor 1 Designated as
Chemerin Receptor 1
Gantz et al. (1996) cloned a novel human gene,
encoding the orphan receptor CMKLR1, which had
sequence and structural homology with a seven-
transmembrane G protein–coupled receptor (GPCR)
(Fig. 2). Samson et al. (1998) cloned what they thought
was a novel human gene encoding the same GPCR,
which they named ChemR23. The receptor is structur-
ally related to receptors for chemokines and other
chemoattractant molecules such as leukotriene B4 and
resolvin D1 (Fig. 3). In 2003, two independent groups
(Meder et al., 2003; Wittamer et al., 2003) identified a
novel chemoattractant in human biologic fluids, the
product of the RARRES2 gene, as the endogenous
ligand for CMKLR1. Wittamer et al. (2003) renamed
the gene product chemerin, and reported that the active
isoform in ascitic fluids was human chemerin21–157,
whereas Meder et al. (2003) found human chemerin21–
154 in hemofiltrate. This pairing was independently
confirmed when Zabel et al. (2005b) identified that
human chemerin21–155 from serum was active at the
CMKLR1 receptor. C9 has been reported as the mini-
mum length of fragment needed to bind and activate
chemerin receptor 1 (Wittamer et al., 2004), retaining a
nanomolar potency in calcium assays. However, further
studies into the activation of different signaling path-
ways suggest that C9 does not mimic fully the actions of
chemerin21–157. C9 exhibits bias, and it is signifi-
cantly less potent at activating b-arrestin recruitment
compared with chemerin21–157 (Kennedy et al., 2016;
see Section VIII. A. Signaling Pathways Activated by
Chemerin Receptor 1). The protein of the CMKLR1 gene
was renamed the chemerin receptor (Davenport et al.,
2013) following confirmation of chemerin as its ligand.
A second chemerin receptor has now been identified;
therefore, CMKLR1 should be designated chemerin re-
ceptor 1 for ligand chemerin (Table 3).
Chemerin receptor 1 is a class AGPCR coupled to Gi/o,
leading to inhibition of adenylyl cyclase and subsequent
cAMP accumulation, intracellular calcium release, and
phosphorylation of mitogen-activated protein kinases
(MAPK) (Wittamer et al., 2003) (see Section VIII. A.
Signaling Pathways Activated by Chemerin Receptor 1).
Human chemerin receptor 1 shares 79% and 80%
sequence identity with rat and mouse chemerin re-
ceptor 1, respectively (Fig. 4). The closest structural
relative to chemerin receptor 1 is orphan receptor GPR1
(Fig. 3), which has since been paired with chemerin (see
Section III. G Protein–Coupled Receptor 1 Designated as
Chemerin Receptor 2).
III. G Protein–Coupled Receptor 1 Designated as
Chemerin Receptor 2
GPR1 was originally cloned by Marchese et al.
(1994b) from a cDNA library of the human hippocam-
pus, and the deduced amino acid sequence revealed the
expected seven-transmembrane domains (Fig. 5). The
GPR1 and CMKLR1 genes share a common ancestor
(Vassilatis et al., 2003) and have a sequence identity of
37% (Fig. 6). The similarities between GPR1 and
CMKLR1 both at the amino acid and gene levels are
shown to be present across various species from lower to
higher vertebrate (fish to human). Porcine GPR1, like
human GPR1 and porcine CMKLR1, is intronless in the
coding region, and computational analysis suggests
almost identical predicted three-dimensional struc-
tures for porcine GPR1 and CMKLR1 (Huang et al.,
2010). Based on the similarities between the two
receptors, Barnea et al. (2008) were the first to identify
chemerin as a ligand for GPR1. They reported that
radiolabeled C9 bound to GPR1 with a subnanomolar
TABLE 2
Nomenclature of chemerin and its receptors
Chemerin Species Gene Protein
Receptor 1 Human CMKLR1 Chemerin receptor 1
Nonhuman cmklr1 Chemerin receptor 1
Receptor 2 Human GPR1 Chemerin receptor 2
Nonhuman gpr1 Chemerin receptor 2
Peptide Human RARRES2 Chemerin
Nonhuman rarres2 Chemerin
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affinity, and both human chemerin21–157 and C13
activated the receptor in a b-arrestin recruitment assay
with a similar nanomolar potency. This pairing has
been independently confirmed by three different groups
(Southern et al., 2013; Rourke et al., 2014; Kennedy
et al., 2016). GPR1 has been suggested to be a functional
chemerin receptor in vivo; characterization of theGPR1
knockout mouse model revealed that GPR1 acts to
modify glucose homeostasis during obesity, in agree-
ment with known functions of chemerin (Rourke et al.,
2014). In light of this, and consistent with International
Union of Pharmacology convention, we recommend that
GPR1 is officially paired with ligand chemerin and
renamed accordingly. As CMKLR1 is chemerin receptor
1, GPR1 should be designated chemerin receptor 2 for
ligand chemerin (Table 4).
Chemerin receptor 2 is a class A GPCR, specifically
the A4 subfamily, but as yet it is largely unknown what
G protein pathway it activates. One study showed that
chemerin modestly induced calcium release (Barnea
et al., 2008). A further study found that chemerin
stimulates RhoA signaling, which was sensitive to
Fig. 2. Amino acid sequence of chemerin receptor 1: Cys112 andCys189 (green) are predicted to form a disulfide bond based on sequence similarity, and
the G protein–binding motif is shown in blue. Figure made using UniProt (Q99788) and Protter (Omasits et al., 2014).
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pertussis toxin (PTX), a highly selective Gai/o inhibitor
(Rourke et al., 2015), suggesting that, similar to
CMKLR1, this receptor could be coupled to Gi/o
(see Section VIII. B. Signaling Pathways Activated by
Chemerin Receptor 2). Human chemerin receptor
2 shares 79% and 80% sequence identity with rat and
mouse chemerin receptor 2, respectively (Fig. 7).
IV. Distribution
A very limited number of studies have investigated
the expression of both CMKLR1 and GPR1 in the same
tissue. To begin to understand whether these chemerin
receptors are expressed differentially or are present
within the same tissues, future studies should identify
both receptors and consider not only the proximity to
ligand chemerin but whether the receptors colocalize. In
addition, an important limitation in the studies of
chemerin expression is that they do not differentiate
between active and inactive chemerin isoforms (dis-
cussed further in Section VI. A. Chemerin Receptor
1 Agonists). Subsequent studies should endeavor to
state which isoform of chemerin is identified using
specific antibodies.
A. Chemerin Receptor 1
1. Humans. In humans, reverse-transcriptase
quantitative polymerase chain reaction has identified
that the CMKLR1 gene is predominately expressed in
dendritic cells, monocytes, and macrophages (Wittamer
et al., 2003; Herová et al., 2015) with high expression
also seen in adipose tissue, spleen, lymph nodes, lung,
skin, adipocytes, vascular smooth muscle cells, endo-
thelial cells, and natural killer cells (Wittamer et al.,
2003; Goralski et al., 2007: Parolini et al., 2007; Kaur
et al., 2010; Kostopoulos et al., 2014; Banas et al., 2015;
Kennedy et al., 2016). Further analysis of CMKLR1
mRNA in the skin showed it is located predominately to
the dermal layer (Banas et al., 2015). CMKLR1 mRNA
was abundantly expressed in adipose tissues (Roh
et al., 2007; Catalán et al., 2013). Immunostaining
followed by fluorescence-activated cell sorter analysis
confirmed that CMKLR1 is expressed on the cell
surface of dendritic cells, monocytes, and macrophages
(Wittamer et al., 2003; Vermi et al., 2005; Zabel et al.,
2005b; Herová et al., 2015). In agreement with the
mRNA expression pattern, immunohistochemistry lo-
calized CMKLR1 expression to smooth muscle cells and
the surrounding adipose tissue of human vessels (aorta,
saphenous vein, coronary artery, mammary arteries,
and resistance vessels) (Kostopoulos et al., 2014;
Kennedy et al., 2016), lung bronchioles (Kennedy
et al., 2016), lymph nodes (Vermi et al., 2005), as well
as the testis (Li et al., 2014b). Western blot detected
high CMKLR1 protein from endothelial cells (Kaur
et al., 2010).
2. Mice. In mice, CMKLR1 mRNA levels were high-
est in white adipose tissue and lung, with lower levels of
expression seen in heart, placenta, kidney, spleen,
brain, liver, testis, skin, ovary, mesenteric lymph nodes,
colon, and thymus (Goralski et al., 2007; Luangsay
et al., 2009; Rourke et al., 2014). CMKLR1 mRNA was
significantly higher in white adipose tissue compared
with brown adipose tissue (Goralski et al., 2007).
Although expression was abundant in both the adipo-
cytes and the stromal vascular fraction of white adipose
tissue (Rourke et al., 2014), there were twofold higher
CMKLR1 mRNA levels in adipocytes and protein
expression was confirmed using immunohistochemistry
(Goralski et al., 2007). Further clarification of the
expression in skin shows that mRNA levels are higher
in the dermal layer (Banas et al., 2015). CMKLR1
protein has also been detected in the b-cells in the islets
of the mouse pancreas (Takahashi et al., 2011).
CMKLR1 mRNA and protein were detected in murine
cardiomyocytes (Rodríguez-Penas et al., 2015). Mono-
clonal antibody staining of ChemR23 showed high
expression in immature plasmacytoid dendritic cells
and at lower levels in myeloid dendritic cells, macro-
phages, and natural killer cells (Zabel et al., 2006;
Luangsay et al., 2009).
3. Rats. In rats, CMKLR1 is expressed in the re-
productive system. High levels of CMKLR1mRNAwere
detected in the testis (Li et al., 2014b) and ovaries
(Wang et al., 2012). This was consistent with immunos-
taining of CMKLR1 expression in Leydig cells (Li et al.,
2014b). In addition, CMKLR1 is expressed in the rat
vasculature. Western blot analysis showed that
CMKLR1 was present in endothelial cells (Zhao et al.,
2013), cardiomyocytes (Zhang et al., 2014), as well as
aorta and mesenteric arteries, and immunostaining
confirmed that expression was in the smooth muscle
media layer and the endothelium (Watts et al., 2013).
4. Other Species. In cows, CMKLR1mRNAhas been
detected in adipose tissue, liver, and mammary gland
(Suzuki et al., 2015), as well as various ovarian cells,
including granulosa and theca cells, corpus luteum, and
oocytes (Reverchon et al., 2014). In ovarian cells from
turkeys, CMKLR1 mRNA was mostly present in theca
Fig. 3. Schematic representation of the structural similarities between
chemerin receptors, CMKLR1 and GPR1, and other chemoattractant
receptors. Sequences for the receptors were aligned to generate the
phylogenetic tree (http://www.phylogeny.fr/). The receptors include
chemokine receptors (CCR2, CCR5, CCR7, and CXCR4), leukotriene B
receptors (BLT1 and BLT2), and formyl peptide receptors (FRP1, FRP2,
and FRP3).
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cells rather than granulosa cells (Diot et al., 2015). In
pigs, CMKLR1 mRNA was present in white adipose
tissue and spleen, with low levels detected in stomach
and lung (Huang et al., 2010).
B. Chemerin Receptor 2
1. Humans. In humans, GPR1 was discovered when
Northern blot analysis identified GPR1 mRNA in the
hippocampus (Marchese et al., 1994b). The same study
reported that GPR1 mRNA was not present in other
brain tissues, including the cerebellum, frontal cortex,
and thalamus, or other peripheral tissues such as
macrophages and monocytes. GPR1 mRNA is also
present in primary brain-derived fibroblast-like cell
lines such as BT-3 and BT-20/N (Shimizu et al., 1999),
mesangial cells (Tokizawa et al., 2000), U87 glioblas-
toma cells, and alveolar macrophages (Farzan et al.,
1997; Yamaguchi et al., 2011). According to the BioGPS
TABLE 3
Classification of chemerin receptor 1
Receptor Structure, Pharmacology,
and Distribution
Receptor Amino Acid Sequences, Pharmacological Parameters,
Tissue Distribution References
Previous Names CMKLR1, ChemR23, ChemerinR, GPCR27, DEZ, RVER1,
TIG2 receptor
Structural information 7TM
Humans 373 aa (UniProt Q99788) chr. 12q24.1 (Entrez 1240)
Rats 371 aa (UniProt O35786) chr. 12q16 (Entrez 60669)
Mice 371 aa (UniProt P97468) chr. 5F (Entrez 14747)
Functional assays CHO cells transfected with CMKLR1 Wittamer et al., 2003; Barnea et al., 2008
Chemotaxis migration assays Wittamer et al., 2003; Vermi et al., 2005;
Zabel et al., 2005b; Albanesi et al., 2009
In vitro pharmacology using isolated
human vessels
Kennedy et al., 2016
In vitro pharmacology using isolated
rat aorta
Watts et al., 2013
Endogenous agonists Human chemerin(21–157)
(pEC50 = 9.37 6 0.05)
Wittamer et al., 2003
RvE1 (pEC50 = 9.37 6 0.05) Arita et al., 2005
Agonists C9 [chemerin(149–157)] Wittamer et al., 2009
C13 [chemerin(145–157)] Wittamer et al., 2003
C15 [chemerin(141–155)] Cash et al., 2008
C19 [chemerin(139–157)] Wittamer et al., 2004
C20 [chemerin(138–157)] Li et al., 2014a
Selective antagonist CCX832 (pIC50 = 8.34 6 0.04) Watts et al., 2013; Kennedy et al., 2016
Radioligands [125I]-C9 (KD = 4.9 nM) Barnea et al., 2008; Kennedy et al., 2016
Human [125I]-chemerin(21–157)
(KD = 0.88 nM)
De Henau et al., 2016
Human [125I]Tyr-[Phe149]-chemerin146–157
(KD = 22 nM)
Wittamer et al., 2003
[3H]RvE1 (KD = 11.3 6 5.4) Arita et al., 2005, 2007
Mouse [125I]-chemerin(21–148)
(EC50 = 1.6 nM)
Zabel et al., 2008; Bondue et al., 2012
Transduction mechanisms Coupled to Gi/o proteins Wittamer et al., 2003; Cash et al., 2008;
Kennedy et al., 2016
Receptor distribution
Humans RT-PCR showed highest expression
of CMKLR1 mRNA in the skin, adipose tissue,
spleen, lymph nodes, and lung
Wittamer et al., 2003; Roh et al., 2007
Immunostaining and FACS analysis
confirmed high expression on dendritic cells,
monocytes, and macrophages
Wittamer et al., 2003; Vermi et al., 2005;
Zabel et al., 2005b; Herová et al., 2015
CMKLR1 protein expression was found on
smooth muscle cells of human vessels
by immunohistochemistry
Kostopoulos et al., 2014
Mice RT-PCR showed highest CMKLR1 expression
in white adipose tissue and the lung
Goralski et al., 2007
CMKLR1 immunoreactivity was
identified in adipocytes
Goralski et al., 2007
Rats RT-PCR–detected CMKLR1 mRNA
were in the reproductive system
(testis and ovary)
Wang et al., 2012; Li et al., 2014b
Western blot analysis and immunohistochemistry
identified CMKLR1 expression in vascular
endothelial cells, cardiomyocytes and the
smooth muscle, and endothelium of
aorta and mesenteric vessels
Watts et al., 2013; Zhao et al., 2013;
Zhang et al., 2014
Tissue function Chemotaxis of leukocytes; adipogenesis;
antimicrobial agent; vasoconstrictor of
saphenous vein and resistance arteries
Wittamer et al., 2003; Goralski et al., 2007;
Cash et al., 2010; Banas et.al., 2013;
Kennedy et al., 2016
aa, Amino acid; chr., chromosome; FACS, fluorescence-activated cell sorter; RT-PCR, reverse-transcription polymerase chain reaction.
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database, GPR1 mRNA is ubiquitously expressed in
humans, with the highest expression seen in the
adrenal cortex, cardiomyocytes, and superior cervical
ganglion (Wu et al., 2009). Reverse-transcriptase
quantitative polymerase chain reaction and im-
munohistochemistry identified GPR1 mRNA and
protein expression in smooth muscle cells of human
vessels (aorta, saphenous vein, coronary artery,
mammary arteries, and resistance vessels), as well
as lung bronchioles and kidney tubules (Karagiannis
et al., 2013; Kennedy et al., 2016). GPR1 mRNA has
also been identified in skin (Banas et al., 2015).
2. Mice. Similar to CMKLR1, in mice, the highest
GPR1 mRNA levels were found in white adipose tissue
(Takahashi et al., 2011); however, GPR1 had a more
ubiquitous expression, with high levels also seen in
skin, brown adipose tissue, skeletal muscle, the brain
(particularly the hypothalamus), bladder, and esopha-
gus, and lower levels detected in heart, lung, liver,
kidney, spleen, and thymus (Regard et al., 2008; Rourke
et al., 2014). In contrast to CMKLR1, GPR1 was
predominately expressed in the stromal vascular frac-
tion of white adipose tissue, not the adipocytes (Rourke
et al., 2014). GPR1 mRNA was also detected in the
ovaries, more precisely with high protein expression in
the oocytes of developing follicles, and in the thecal cells,
granulosa cells, luteal cells, and interstitial cells of the
stroma (Yang et al., 2016).
3. Rats. To date, only one study has characterized
the expression pattern of GPR1 in rats, specifically in
the male reproductive system. GPR1 mRNA was most
highly expressed in the testis, withmoderate expression
in prostate and epididymis fat (Li et al., 2014b). As a
control tissue, the authors also report very little expres-
sion of GPR1 mRNA in the liver.
4. Other Species. Like CMKLR1 expression, GPR1
mRNA was detected in adipose tissue, liver, and
mammary gland, and ovarian cells in cows (Reverchon
et al., 2014; Suzuki et al., 2015) and ovarian cells in
turkeys (Diot et al., 2015). In pigs, GPR1 was expressed
in kidney, white adipose tissue, spleen, and liver
(Huang et al., 2010).
C. Chemerin
1. Humans. In humans, a RNA array discovered
that chemerin mRNA was widely expressed in many
Fig. 4. Clustal Omega (http://www.uniprot.org/align) sequence alignment of the human, rat, and mouse chemerin receptor 1. Identical amino acids in
all species, “*”; conserved amino acid substitution, “:”; and semiconserved amino acid substitution, “.” Blue boxes highlight the transmembrane
domains, and the pink line identifies the G protein–binding motif.
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tissues. The highest expression was seen in the liver,
pancreas, adrenal gland, and skin, but expression was
also detected in lymph nodes, heart, and ileum (Zabel
et al., 2005b). Another study identified that high levels
of chemerin mRNA were present in the liver, lung,
pituitary gland, and ovary (Wittamer et al., 2003). This
is consistent with the BioGPS database, which identi-
fied the most chemerin mRNA in liver, adrenal cortex,
and lung (Wu et al., 2009). Further studies into
the precise location of chemerin mRNA in the skin
revealed that, in contrast to its receptors, chemerin is
predominately expressed in the epidermis (Banas et al.,
2015). Northern blot analysis confirmed that chemerin
mRNA was highly expressed in liver and pancreas
(Takahashi et al., 2011). Immunohistochemistry local-
ized chemerin to the cardiovascular system, including
the pericoronary and periaortic adipose tissue, specifi-
cally to adipocytes and stromal vascular cells
(Kostopoulos et al., 2014). In addition, chemerin was
detected in vascular smooth muscle cells and endothe-
lial cells of human vessels (aorta, saphenous vein,
coronary artery, mammary arteries, and resistance
Fig. 5. Amino acid sequence of chemerin receptor 2: Cys110 and Cys187 (green) are predicted to form a disulfide bond based on sequence similarity, and
the G protein–binding motif is shown in blue. Figure made using UniProt (P46091) and Protter (Omasits et al., 2014).
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vessels), endocardial endothelial cells, epithelial cells of
the lung bronchioles, and tubules and endothelial cells
in the kidney (Kennedy et al., 2016).
2. Mice. In mice, similar to that found in humans,
chemerin mRNA was detected in a wide range of
different tissues. The highest expression was seen in
liver, skin, white adipose tissue, and placenta (Goralski
et al., 2007; Banas et al., 2015), but chemerin mRNA
was also present in ovary, skin, lung, liver, ilieum,
colon, testis, thymus, spleen, mesenteric lymph nodes,
and Peyer’s patches (Luangsay et al., 2009; Yang et al.,
2016). ChemerinmRNA levels were significantly higher
in white adipose tissue compared with brown, and they
were more abundant in adipocytes than in the stromal
vascular fraction of white adipose tissue, a similar
expression pattern to its receptor CMKLR1 (Goralski
et al., 2007). Also, like CMKLR1, chemerin protein was
localized to b-cells in islets of the pancreas (Takahashi
et al., 2011).
3. Rats. In rats, chemerin mRNA is predominately
expressed in the liver and adipose tissue (Watts et al.,
2013; Li et al., 2014b). Immunohistochemistry con-
firmed expression of chemerin in the perivascular
adipose tissue surrounding aorta and mesenteric ar-
teries (Watts et al., 2013). Chemerin mRNA has also
been detected in rat ovaries (Wang et al., 2012).
4. Other Species. Similar to other species, high
levels of chemerin mRNA were seen in adipose tissue
and liver of cows (Suzuki et al., 2015) and pigs (Huang
et al., 2010) as well as liver of turkeys (Diot et al., 2015).
The expression pattern of chemerin mRNA in ovarian
cells from cows and turkeys is consistent with that of its
receptors (Reverchon et al., 2014; Diot et al., 2015).
V. Radiolabeled Ligands
Two independent studies have carried out saturation-
binding analysis in cells artificially expressing either
human CMKLR1 or human GPR1 to determine the
dissociation constant, KD values of [
125I]Tyr149-C9 at
each receptor. Barnea et al. (2008) report KD values for
CMKLR1 and GPR1 as 4.9 and 5.3 nM, respectively,
and show that both human chemerin21–157 (IC50 = 0.15
nM, CMKLR1 and 0.23 nM, GPR1) and unlabeled C13
(IC50 = 1.9 nM, CMKLR1 and 2.3 nM, GPR1) compete
for all the binding at both receptors. Kennedy et al.
(2016) report KD values of 0.3 and 0.9 nM for CMKLR1
and GPR1, respectively, and found that unlabeled C9
competed for all the binding at both receptors (pKi =
9.21 6 0.14, CMKLR1 and 8.81 6 0.17, GPR1). Sub-
sequent studies in human cardiovascular tissues
showed 125I-C9 bound specifically, saturably, and re-
versibly to a single site in human saphenous vein,
identified as CMKLR1, with a KD = 0.53 6 0.31 nM
and Bmax = 0.05 6 0.007 fmol/mg and a hill slope of
1 (Kennedy et al., 2016).
Fig. 6. Clustal Omega (http://www.uniprot.org/align) sequence alignment of the human CMKLR1 and GPR1. Identical amino acids in all species, “*”;
conserved amino acid substitution, “:”; and semiconserved amino acid substitution, “.” Blue boxes highlight the transmembrane domains.
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Further characterization of human CMKLR1 has
been carried out with other radiolabeled ligands in
transfected cells. Derived from human chemerin146–
157, in which Tyr149 has been replaced by a phenylal-
anine and an N-terminal tyrosine added, the peptide
YHSFFFPGQFAFS was radioiodinated on tyrosine
residue, [125I]Tyr-[Phe149]-chemerin146–157 (Wittamer
et al., 2003). [125I]Tyr-[Phe149]-chemerin146–157 bound
to cells transfected with human CMKLR1 with a KD =
22 nMcalculatedusing a single-sitemodel. Chemerin21–
157, chemerin139–157, and C9 (pIC50 = 8.186 0.27; 7.70
6 0.07; and 8.26 6 0.09, respectively) all competed for
radiolabeled binding with a similar affinity (Wittamer
et al., 2004).
Although the shorter fragments of chemerin are
useful tool compounds, further study into the binding
of full-length human chemerin to human CMKLR1 and
GPR1 is required to understand how the endogenous
ligand binds to its receptors. Although there are the
obvious limitations of radiolabeling a 143-amino-acid
protein, two groups have shown that larger fragments of
chemerin can be radiolabeled in their studies on mouse
CMKLR1. Radiolabeled human chemerin21–148 bound
to native CMKLR1 receptors on wild-type (WT) mouse
macrophages with a calculated KD = 1.2 nM, and
binding to macrophages from CMKLR1-deficient mice
was significantly reduced (Bondue et al., 2012). Simi-
larly, Zabel et al. (2008) show binding of this radiolabel
to mouse CMKLR1 with an EC50 = 3.1 nM. Most
recently, De Henau et al. (2016) have importantly
shown that human [125I]chemerin(21–157) binds to
Chinese hamster ovary (CHO)-K1 cells transfected with
CMKLR1 and GPR1 with KD of 0.88 and 0.21 nM,
respectively.
Subsequent studies should investigate binding to the
receptor with the endogenous ligand from the same
species. The structure of chemerin is described as a
mirror-image, reverse chemokine (Zabel et al., 2006)
with an N-terminal core region and a flexible
C-terminal region that needs to be cleaved for receptor
TABLE 4
Classification of chemerin receptor 2
Receptor Structure, Pharmacology, and
Distribution
Receptor Amino Acid Sequences, Pharmacological Parameters,
Tissue Distribution References
Previous names GPR1
Structural information 7TM
Humans 355 aa (UniProt P46091) chr. 2q33.3 (Entrez 2825)
Rats 353 aa (UniProt P46090) chr. 9q31
(Entrez 25457)
Mice 353 aa (UniProt Q8K087) chr. 1C2
(Entrez 241070)
Functional assays CHO cells transfected with GPR1 Barnea et al., 2008; Kennedy et al., 2016
Endogenous agonists Human chemerin(21–157) (pEC50;9) Barnea et al., 2008; Southern et al., 2013;
Kennedy et al., 2016
Agonists C9 [chemerin(149–157)]
(pEC50 = 8.65 6 0.14)
Kennedy et al., 2016
C13 [chemerin(145–157)]
(pEC50 = 9.05 6 0.09)
Kennedy et al., 2016
C20 [chemerin(138–157)] Li et al., 2014a
Selective antagonist None
Radioligands [125I]-C9 (KD = 5.3 nM)
(pIC50 = 9.3)
Barnea et al., 2008; Kennedy et al., 2016
Human [125I]-chemerin(21–157)
(KD = 0.21 nM)
De Henau et al., 2016
Transduction mechanisms Coupled to Gi/o proteins: predicted Rourke et al., 2015
Receptor distribution
Humans Northern blot analysis identified the
GPR1 gene in the hippocampus
Marchese et al., 1994b
RT-PCR showed highest expression of
GPR1 mRNA in the adrenal cortex,
cardiomyocytes, and superior cervical ganglion
Wu et al., 2009
Immunohistochemistry confirmed GPR1
expression in smooth muscle cells
of the vasculature
Karagiannis et al., 2013; Kennedy et al.,
2016
Mice RT-PCR identifed highest GPR1 mRNA
expression in white adipose tissue
(predominately the stromal vascular fraction),
with high levels also detected in skin,
brown adipose tissue, skeletal muscle, the brain
(particularly the hypothalamus), bladder,
esophagus, and ovaries
Regard et al., 2008; Takahashi et al., 2011;
Rourke et al., 2014; Yang et al., 2016
Rats RT-PCR detected GPR1 mRNA in
the male reproductive system, with
high levels in the testis
Li et al., 2014b
Tissue function HIV/SIV coreceptor; lipid metabolism Edinger et al., 1997; Shimizu et al., 2009;
Rourke et al., 2014
aa, Amino acid; chr., chromosome; RT-PCR, reverse-transcription polymerase chain reaction; SIV, simian immunodeficiency virus.
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activation. It would therefore be insightful to under-
stand how the different regions bind to the receptors
and whether this in turn alters the downstream signal-
ing pathways that are activated. Chemokines bind to
their receptors in a two-site model (Clark-Lewis et al.,
1995), and chemerin binding could be similar. It has
emerged that the shorter C-terminal fragments of
chemerin are biased toward the G protein pathway
comparedwith b-arrestin (seeSectionVIII. A. Signaling
Pathways Activated by Chemerin Receptor 1); therefore,
the N-terminal core region of chemerin could be re-
quired for activation of the latter pathway.
In addition, [3H]-resolvin E1 (RvE1) binds to a single
site on CMKLR1-transfected cells with a high affinity
(KD = 11.3 6 5.4 nM, Bmax = 4200 6 1050 binding sites
per cell), which is blocked by 10 mM chemerin peptide
(Tyr-[Phe149]-chemerin146–157), suggesting that they
have the same recognition site within the receptor
(Arita et al., 2005).
VI. Agonists
A. Chemerin Receptor 1 Agonists
The endogenous agonist of CMKLR1 is the chemo-
attractant chemerin derived from the RARRES2 gene.
Wittamer et al. (2003) isolated an active fraction of
human ascitic fluids and found that, after tryptic digest
and mass spectrometry, eight peptide products were
predicted to originate from the RARRES2 gene. The
C-terminal peptide was not tryptic, suggesting that the
active isoform, lacking six amino acids, was a result of
proteolytic cleavage of a precursor. Chemerin21–157
bound to and was functionally active at the CMKLR1
receptor with a low nanomolar potency (EC50 = 4.56 0.7
nM), whereas precursor, prochemerin, was 50–100
less potent (EC50 = 393 6 116) (Wittamer et al., 2003).
Meder et al. (2003) similarly identified that a product of
the RARRES2 gene, modified at the N and C terminus,
activated CMKLR1; however, they found that the
circulating active form was chemerin21–154 (no EC50
value given). Human serum had abundant chemo-
attractant activity at CMKLR1 due to circulating
chemerin21–155 (no EC50 value given), an eight
C-terminal amino acid truncation of prochemerin
(Zabel et al., 2005b). The activity of chemerin in serum
was lost on addition of protease inhibitors, confirming
that proteolytic processing of the C terminus is required
to convert prochemerin into the bioactive form, and this
occurs post-translationally by various serine (Zabel
et al., 2005a) and cysteine proteases (Kulig et al.,
2011). It is not well characterized what the active
fragment of chemerin is in humans, or whether different
Fig. 7. Clustal Omega (http://www.uniprot.org/align) sequence alignment of the human, rat, and mouse chemerin receptor 2. Identical amino acids in
all species, “*”; conserved amino acid substitution, “:”; and semiconserved amino acid substitution, “.” Blue boxes highlight the transmembrane
domains; the pink line identifies the G protein–binding motif; and the box highlights the differing sequence in humans.
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lengths are found in different environments and have
different functions. This is a key area of research that
needs to be understood in the field of chemerin and its
receptors. Like in the localization studies, many studies
comparing plasma levels of chemerin with disease
measure chemerin immunoreactivity without differen-
tiating whether it is prochemerin, active chemerin, or
degradation products. Future experiments should con-
sider that prochemerin is not biologically active, and
therefore measurements of chemerin levels should pre-
cisely identify cleavage of this precursor. This in turn
will give us important knowledge regarding chemerin
as an agonist, and the active fragments can then be
characterized pharmacologically.
The studies by Meder et al. (2003) and Zabel et al.
(2005b) did not characterize the pharmacology of
chemerin21–154 and chemerin21–155 at the human
CMKLR1 receptor. Their functional findings are in
contrast to later work by Wittamer et al. (2004), who
carried out extensive in vitro studies to identify the
residues of chemerin necessary for activation and func-
tion at human CMKLR1. Peptides of different lengths
were synthesized, and their activities tested against
human CMKLR1-transfected cells in a calcium assay.
Chemerin139–157 (EC50 = 16.76 3.2 nM) retainedmost
of the activity of chemerin21–157, and, as expected, the
prochemerin equivalents, chemerin139–163 and
chemerin158–163, lost all biologic activity. Interest-
ingly, removal of one, two, or three amino acids,
chemerin139–156 (EC50 = 97 6 13 nM), chemerin139–
155, and chemerin139–154, or addition of one amino
acid, chemerin139–158, all led to a significant drop in
potency. This confirms that precise cleavage at the C
terminus to the serine residue at position 157 is critical
for activity. In agreement, the work of Li et al. (2014a)
reports C20, chemerin138–157 (competition binding
IC50 = 1.6 nM, functional response from 1 nM), as a
potent agonist at CMKLR1. C20 corresponds to an
evolutionary conserved region of the mature protein
flanked by potential cleavage sites. Further C-terminal
peptides from the human sequencewere synthesized, by
Wittamer et al. (2004), to identify the shortest peptide
with the highest potency. Truncating the N terminus to
give C13 (pD2 = 7.85 6 0.01) or C9 (pD2 = 8.15 6 0.02)
retained similar activity to human chemerin21–157;
however, further removal of the N-terminal tyrosine to
the eight-amino-acid peptide, chemerin150–157,
resulted in a significant drop in potency. Alanine-
screening mutagenesis identified the aromatic resi-
dues Tyr149, Phe150, Phe154, and Phe156, as well as
Gly152, as important residues that likely contribute to
direct interaction between chemerin and CMKLR1
(Wittamer et al., 2004).
Similarly, to investigate the binding and function of
chemerin at mouse CMKLR1, Cash et al. (2008) syn-
thesized different fragments derived from the C termi-
nus of mouse chemerin. They identified that C15
retained most of the activity of mouse chemerin17–
156 in a macrophage chemotaxis assay (no EC50 values
given); however, mouse chemerin144–154, chem-
erin144–156, and chemerin138–156 were significantly
less effective or had no effect in inhibiting induced
cytokine production. The authors have since shown that
C15 enhanced macrophage phagocytosis, leading to
improved microbial particle clearance and apoptotic
neutrophil ingestion (Cash et al., 2010), and inhibited
intravascular inflammatory events to accelerate wound
closure and reduce scarring (Cash et al., 2014). How-
ever, over the course of these studies, the pharmacology
of this peptide has not been characterized, and these
findings are in contrast to others who report no activity
in cells transfected with CMKLR1. Shimamura et al.
(2009) found that amino acids Phe155 and Ser156 in
mouse chemerin were essential for activity at themouse
CMKLR1 receptor, and that the equivalent mouse
peptide to human C9, mouse chemerin148–156, acti-
vates the mouse receptor with comparable potency to
mouse chemerin17–156. Rourke et al. (2015) also report
that C15 did not activate the serum-response factor
luciferase signaling assay or b-arrestin recruitment via
either mouse or human CMKLR1. C15 is therefore a
controversial agonist of the CMKLR1 receptor; many
academic and industry groups are unable to reproduce
the findings that this is an active compound. As they
have not yet been performed, must-do experiments to
clarify the role of this peptide include radioligand
saturation and competition-binding experiments and
pharmacological profiling in different signaling assays,
with negative results as valuable as positive.
As discussed in Section VIII. A. Signaling Pathways
Activated by Chemerin Receptor 1, biased signaling has
been reported at CMKLR1 (Kennedy et al., 2016). This
selective activation of a downstream pathway over another
bydifferentagonists couldbeanexplanation for theat times
confusing and contradictory results seen for chemerin
agonists at CMKLR1. Human chemerin21–155, human
chemerin21–154, and C15, reported to be functionally
active, may not activate the specific downstream signal-
ing pathways tested by others, and thus appear inactive
in those studies. To understand this, the full pharmacol-
ogy of chemerin agonists in binding and multiple down-
stream signaling pathways needs to be carried out.
CellKey or EPIC dynamic mass redistribution assays
that monitor activation of all downstream signaling
pathways should be used to confirm activation of the
receptor by these controversial agonists.
RvE1, an oxygenated product of the essential fatty acid
eicosapentaenoic acid, is a potent anti-inflammatory and
proresolving mediator and has been shown to acti-
vate CMKLR1. Arita et al. (2005) found that in
CMKLR1-transfected HEK293 cells, RvE1 caused a
concentration-dependent inhibition of tumor necrosis
factor (TNF)-a–induced nuclear factor-kB activation
with an EC50 of 1.0 nM. Further studies by the same
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laboratory confirmed that RvE1 binds to CMKLR1-
transfected CHO cells in a concentration-dependent
manner (Ohira et al., 2010) and stimulates b-arrestin
recruitment (EC50 = 13 pM) (Krishnamoorthy et al.,
2010) and adenosine diphosphate activation of human
platelets in a CMKLR1-dependent manner (Fredman
et al., 2010). One independent study has identified the
same pairing, showing that RvE1-induced proliferation
of fibroblasts was inhibited by CMKLR1 small interfer-
ing RNA (Qu et al., 2012), but others were unable to
reproduce these findings (Luangsay et al., 2009;
Davenport et al., 2013). Bondue et al. (2011b) also
suggest that there is uncertainty because a later study
by Arita et al. (2007) identified a structurally similar
receptor, leukotriene B4 receptor BLT1, that mediates
RvE1 activities. Although a previous review is convinced
(Bäck et al., 2014), to date the pairing of RvE1 and
CMKLR1 has not been confirmed, and further studies
are required to clarify this area.
One study (Peng et al., 2015) has shown that the
amyloid-b peptide (Ab42) conjugated to fluorescein iso-
thiocyanate binds to rat basophilic leukemia cells stably
transfected with CMKLR1 with KD = 0.8 6 0.2 mM. The
authors report functional activity of Ab42 (maximum at
2 mM), similar to C9 in induction of chemotaxis of
primarymicroglia cells.However, further studies showed
that Ab42 and C9 stimulated different pathways in this
cell line, Ab42 does not induce Ca2+ release, but induced
chemotaxis, whereas C9 induced Ca2+ and chemotaxis.
No other groups have reported actions of Ab42 on
CMKLR1, and so confirmation of this pairing is required.
B. Chemerin Receptor 2 Agonists
Recombinant human chemerin and C-terminal pep-
tides, C9 and C13, are the only known agonists of GPR1.
b-arrestin recruitment studies on cells transfected with
human GPR1 have given insight into its potential
endogenous agonists. Human chemerin21–157 has been
reported to be a potent agonist at human GPR1 with a
subnanomolar potency (pD2 = 9.6, Barnea et al., 2008; pD2
= 8.8, Southern et al., 2013; pD2 = 9.1, Kennedy et al.,
2016), with one group reporting a lower potency of pD2 =
7.7 (Rourke et al., 2014). C9 andC13 activateGPR1with a
similar potency to chemerin, pD2 = 8.09 6 0.16, 8.65 6
0.14, and 9.05 6 0.09, respectively; however, they appear
to be partial agonists comparedwith chemerin, with lower
maximum responses, Emax = 71% 6 5%, 97% 6 3%, and
134%6 6% response of C13, respectively (Kennedy et al.,
2016). In addition, human chemerin21–157 and mouse
chemerin17–156 have been shown to activate gene ex-
pression via both human and mouse GPR1 in vitro
(Rourke et al., 2015). The next step is to confirm that
endogenous chemerin, present in humans, binds and
activates GPR1, and, as for CMKLR1, it will then be vital
to begin tounderstandwhat lengths of chemerinare found
endogenously and whether different lengths have differ-
ent functions via this receptor.
VII. Antagonists
C-terminal processing of prochemerin has resulted in
a number of agonists with different affinities and
potencies. One hypothesis that has emerged is that
the different isoforms compete at the chemerin recep-
tors to exert their actions through different signaling
pathways. One group identified that chemerin21–155
had no agonistic activity at CMKLR1 but inhibited
chemerin21–157–induced Ca2+ flux by 50% (Yamaguchi
et al., 2011), suggesting that it is acting as antagonist.
Similarly, Peng et al. (2015) report that C15 blocked the
response Ab42 at CMKLR1. This complicates further
the nature of chemerin processing and signaling,
but could also offer a reason why C15 appears to have
anti-inflammatory effects (Cash et al., 2008) in con-
trast to proinflammatory actions of other isoforms
(Wittamer et al., 2003). This idea can be easily investi-
gated pharmacologically, using cells transfected with
CMKLR1 or GPR1 and different signaling readouts;
known chemerin agonists can be incubated as antago-
nists first before addition of a second chemerin agonist.
A small-molecule antagonist, CCX832, designed and
synthesized by Chemocentryx (Mountain View, CA), is
reported to be a CMKLR1 antagonist. It has a nanomolar
IC50 for the receptor in humans (2.4 nM), rats (2 nM), and
mice (5 nM) calculated through radiolabeled binding
assays, and similar affinities were found in functional
calcium mobilization and chemotaxis experiments (Watts
et al., 2013). Further characterization of the compoundwas
carried out on CHO cells transfected with either human
CMKLR1 or GPR1 to explicitly confirm its selectivity both
in binding and functional assays. Kennedy et al. (2016)
showed that CCX832 competed for radiolabeled C9 bind-
ing toCMKLR1 (pKi =9.1660.42), butnotGPR1, and that
CCX832 blocked C9-mediated b-arrestin recruitment at
CMKLR1 (pA2 = 8.32 6 0.04), but had no effect on the C9
response at GPR1. Further confirmation of the compound
selectivity has beenhighlighted byusing silencingRNA. In
mesenchymal stromal cells, chemerin significantly in-
creased cell migration, and this effect was blocked by
CCX832, mimicking the effect of CMKLR1 knockdown
cells, whereas GPR1 knockdown cells had no effect on the
chemerin response (Kumar et al., 2014). CCX832 has been
demonstrated to block chemerin-induced vasoconstriction
in rat aorta (Watts et al., 2013) and human vessels
(Kennedy et al., 2016) in vitro, inhibit chemerin-induced
increase in mean arterial blood pressure in rats in vivo
(Kennedy et al., 2016), and affect cell migration in the
development of cancers (Kumar et al., 2014, 2016).
CCX832 is therefore a highly selective CMKLR1 antago-
nist and can be used as a definitive means to differentiate
the response of chemerin at chemerin receptor 1.
One further small-molecule 2-(anaphthoyl) ethyltri-
methylammonium iodide (a-NETA; Fig. 1D), originally
identified as a choline acetyltransferase inhibitor, has
also been reported as a CMKLR1 antagonist (Graham
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et al., 2014). Measuring b-arrestin recruitment, using
CHO cells transfected with human CMKLR1, a-NETA
had an IC50 of 0.38 mM. In experimental autoimmune
encephalomyelitis, a model for human multiple sclero-
sis, a-NETA significantly delayed the onset of the
disease in agreement with that seen in CMKLR1-
deficient mice. The authors note the limitations
of selectivity with this compound, specifically that
a-NETA has an IC50 of 3.4 mM to GPR1-transfected
cells, only 10-fold less potent than CMKLR1.
Most recently, nanobodies (CA4910 and CA5183)
targeted toward the CMKLR1 receptor have been de-
veloped (Peyrassol et al., 2016). The authors report that
these nanobodies bind to the same binding site as
chemerin on CMKLR1 and antagonize chemerin-
mediated intracellular calcium release and chemotaxis
of human monocyte-derived dendritic cells.
The existence of two chemerin receptors necessitates
that for each function of chemerin the target needs to be
explicitly characterized through imaging of receptor
distribution and pharmacologically. However, a lack of
available selective antagonists for these receptors is a
current struggle in the field. At this stage, it is only
possible to decisively state functionality through
CMKLR1 using selective compound CCX832, which is
not commercially available. There is not yet an antag-
onist for GPR1, and this needs to be developed to
identify the function of GPR1 in humans. Further
pharmacological studies are necessary to identify dif-
ferences in amino acid residues activated in the GPR1
receptor by chemerin compared with CMKLR1 that
could be exploited to design and synthesize selective
antagonists. Based on the receptor sequences, CMKLR1
(Fig. 2) has a larger extracellular loop 2 thanGPR1 (Fig.
5). It is not yet known what this means pharmacolog-
ically, but this could be useful in the development of
selective compounds. An alternative would be to carry
out a high-throughput screen using expressed GPR1
receptors, but this may require further evidence that
blocking GPR1 would represent a new therapeutic
target to justify investment.
VIII. Receptor Signaling
A. Signaling Pathways Activated by Chemerin
Receptor 1
Current knowledge of the signaling pathways down-
stream of CMKLR1 has predominately come from
assays in cell lines and demonstrates that this receptor
couples to the Gai/o signaling pathway, causing release
of intracellular Ca2+ (Wittamer et al., 2003; Kaneko
et al., 2011) and inhibition of cAMP accumulation
(Kennedy et al., 2016). A study using bioluminescence
resonance energy transfer–based biosensors confirmed
that chemerin21–157 and C9 activated three Gai
subtypes (Gai1, Gai2, and Gai3) and the two Gao iso-
forms (Gaoa and Gaob) with a comparable potency to the
binding affinity (De Henau et al., 2016). In addition, a
number of studies have reported downstream signaling
through other pathways, including phosphorylation of
extracellular signal-regulated kinases 1/2 and MAPK
(Wittamer et al., 2003; Goralski et al., 2007; Sell et al.,
2009; Hart and Greaves, 2010; Kaneko et al., 2011;
Lobato et al., 2012) and activation of RhoA (Rourke
et al., 2015), all of which are sensitive to PTX, and
b-arrestin recruitment (De Henau et al., 2016; Kennedy
et al., 2016). Experiments identifying which residues in
the human receptor are involved in downstream signal-
ing have not yet been carried out. At the rat receptor, it
has been shown that Ser343 is necessary for phosphor-
ylation by GPCR kinase and Ser347 by phosphokinase C
(Zhou et al., 2014).
Most recently, it has been discovered that chemerin
agonists can selectively signal through different path-
ways via CMKLR1. Intriguingly, C9 and C13 weremore
potent (pD2 = 9.396 0.09 and 9.126 0.12, respectively)
than human chemerin21–157 (pD2 = 8.45 6 0.10) in G
protein–dependent cAMP inhibition assays, but less
potent (pD2 = 7.096 0.06, and 7.156 0.04, respectively)
at inducing b-arrestin recruitment compared with
chemerin21–157 (pD2 = 9.37 6 0.05) (Kennedy et al.,
2016). C9 and C13 preferentially activated cAMP in-
hibitionwith a bias factor of;5000. This could suggest a
trend for shorter C-terminal fragments of chemerin to
be strongly biased toward activation of G protein
pathway. Biased signaling was previously proposed at
the CMKLR1 receptor. Peng et al. (2015) presented
Ab42 as a biased ligand due to its ability to promote
chemotaxis and internalize CMKLR1, but, unlike other
chemerin ligands, it had no effect on Ca2+ flux, and
Rourke et al. (2015) hypothesized the possibility, al-
though it was beyond the scope of their downstream
signaling study. This finding suggests that endogenous
chemerin fragments could have the potential to exhibit
a spectrum of activities at different signaling pathways
and could offer an alternative explanation for differing
activities of chemerin agonists (see Section VI. A.
Chemerin Receptor 1 Agonists).
It is possible that there is crosstalk between chemerin
and other cytokines and their receptors. For example, it
has been reported that CMKLR1 can form heterodimers
with chemokine receptor CCR7 and CXCR4 (de Poorter
et al., 2013) and that chemerin signaling synergises
with CCL7 to produce significantly greater monocyte-
derived dendritic cell migration than the additive re-
sponse of the two ligands alone (Gouwy et al., 2014).
Although this has not been reported specifically for
CMKLR1 (as opposed to GPR1), it is likely in monocyte-
derived dendritic cells that CMKLR1 is present. As seen
for other cytokines, activation of a GPCR stimulates
multiple coinciding signaling pathways that could
synergise within the cell to give an amplified cellu-
lar response (Gouwy et al., 2005). In primary hu-
man hepatocytes, CMKLR1 was upregulated by the
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adipokine, adiponectin, with receptor expression signif-
icantly reduced in liver of adiponectin-deficient mice
(Wanninger et al., 2012). In contrast, adiponectin down-
regulated CMKLR1 in bovine mammary epithelial cells
(Suzuki et al., 2015). This suggests that other adipo-
kines could influence CMKLR1 expression.
It has been implicated that CMKLR1 may signal
through BMP4 to regulate estrogen and progesterone
secretion in polycystic ovary syndrome (Tang et al.,
2016), although this mechanism has not been fully
delineated.
B. Signaling Pathways Activated by Chemerin
Receptor 2
The high-sequence identity of GPR1 with CMKLR1
has not only led to the pairing of this receptor with
chemerin, but also allowed extrapolation of what sig-
naling pathways the orphan receptor couples to. The G
protein–coupling specificity of GPR1 was predicted
using the receptor sequences from humans and mice
and PRED-COUPLE 2.0 software. The results showed
that both GPR1, in humans and mice, was predicted to
couple to Gaq/11 and Gai/o (Rourke et al., 2015). In
agreement with this prediction, the authors used cell-
based assays with either human or mouse GPR1-
transfected cells and found that chemerin activated
the RhoA/RhoA kinase signaling at GPR1 and this was
completely blocked by PTX. This suggests that, like
CMKLR1, GPR1 is coupled to Gai/o. In addition, GPR1
was also found to modestly activate the MAPK/extra-
cellular signal-regulated kinase pathway. At this early
stage of discovery, much is still to be elucidated around
GPR1 signaling, as yet no studies have identified
specific residues involved in receptor signaling.
GPR1 has a mutation in G protein–binding motif
DRY: a highly conserved motif at the end of trans-
membrane helix 3 involved in GTP/GDP exchange in G
protein activation (Oldham and Hamm, 2008). A study
by Rovati et al. (2007) shows that a nonconservative
arginine mutation does not affect arrestin recruitment;
however, it disrupts receptor function by reducing
agonist-induced G protein activity. In human GPR1,
the motif is mutated to DHY (Figs. 5 and 7), the
histamine residue; although regarded as a conservative
replacement of the arginine residue, it could affect G
protein binding and therefore signaling at this receptor.
Barnea et al. (2008) report that activation of GPR1
stimulated Ca2+ flux; although it was at low levels
comparedwith that exerted by CMKLR1 and in CellKey
experiments, human chemerin21–157, C9, and C13
were less potent at activating GPR1 than in b-arrestin
recruitment assays (unpublished data). In a biolumi-
nescence resonance energy transfer–based binding as-
say, activation of GPR1 by chemerin did not induce
binding of any G protein, but only b-arrestin (De Henau
et al., 2016). These findings require further investiga-
tion: key experiments would exploit technology such as
the CellKey system to test chemerin activation of GPR1-
transfected and CMKLR1-transfected cells in parallel
to compare the response size. In addition, Marchese
et al. (1994a) highlight an interesting observation: rat
GPR1 has 77% sequence identity with the human
receptor, but it has the conserved arginine residue of
the DRY motif like other GPCRs. Mouse GPR1 also has
the conserved DRY motif. Using rodent GPR1- and
human GPR1-transfected cells in the above-mentioned
assay would be a valuable comparison to test the effect
of the mutation. Worthy of note is that in CMKLR1 the
“DRY”motif is “DRC” across species (Figs. 2 and 4). This
is a known modification of the G protein–binding motif
that does not affect signaling (Rovati et al., 2007).
IX. Physiologic Roles
A. Chemerin Receptor 1
1. Immunity. The specific expression pattern of
CMKLR1 on dendritic cells andmacrophages highlights
the key function of this receptor in innate and adaptive
immunity. Chemerin-stimulated recruitment of these
antigen-presenting cells suggests that this receptor can
initiate an early immune response (Mariani and Ron-
cucci, 2015). It is well characterized that chemerin is a
proinflammatory chemotactic agent that through acti-
vation of CMKLR1 causes the transmigration of den-
dritic cells and macrophages in humans (Wittamer
et al., 2003; Vermi et al., 2005; Zabel et al., 2005b,
2006; Albanesi et al., 2009; Skrzeczynska-Moncznik
et al., 2009b; De Palma et al., 2011) and mice (Hart
and Greaves, 2010; Gonzalvo-Feo et al., 2014).
CMKLR1 has been implicated in the development of
the immune response by stimulating recruitment of
natural killer cells (Parolini et al., 2007; Skrzeczynska-
Moncznik et al., 2009a). A handful of studies inmice has
reported that chemerin also exhibits anti-inflammatory
effects via CMKLR1. C15 enhanced macrophage phago-
cytosis, leading to improved microbial particle clear-
ance and apoptotic neutrophil ingestion (Cash et al.,
2010) and increased macrophage adhesion capacity
(Hart and Greaves, 2010). RvE1 enhanced human
macrophage phagocytosis via CMKLR1 (Ohira et al.,
2010), and similarly, it has been shown in mice in vivo
(Schwab et al., 2007) and in vitro (Hong et al., 2008). In
addition, chemerin reduced neutrophil inflammation
and inhibited the release of inflammatory cytokines in a
mouse model of lung inflammation (Luangsay et al.,
2009). The differing proinflammatory and anti-
inflammatory effects of CMKLR1 could be due to
activation of the receptor by different isoforms of
chemerin, or it could suggest that the chemer-
in/CMKLR1 signaling pathway can activate and limit
its actions depending on the environment it is
mediating.
2. Antibacterial/Antimicrobial Agent. Based on the
structure of chemerin, it is predicted to belong to the
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cathelicidin/cystatin family of proteins, which includes
the antibacterial polypeptides cathelicidins, suggesting
that chemerin could play a role in host defense.
Chemerin is highly abundant in human skin and has
been identified as an antimicrobial and antibacterial
reagent, significantly inhibiting bacteria growth in vitro
(Kulig et al., 2011; Banas et al., 2013). Keratinocytes
respond to microbial stimuli by producing chemerin.
The epidermis of the skin responds to some bacterial
strains through upregulation of CMKLR1, which is
likely to respond to chemerin in an autocrine manner
to give chemerin its antimicrobial functionality (Banas
et al., 2015).
3. Adipogenesis and Energy Metabolism. In 2007,
the important discovery of chemerin and CMKLR1
expression in adipose tissue (Goralski et al., 2007)
changed our comprehension of chemerin biology. Chem-
erin and CMKLR1 have been found to be important
regulators of adipogenesis. Expression of both increases
throughout maturation of periadipocytes in humans
(Roh et al., 2007; Sell et al., 2009), mice (Goralski et al.,
2007), and cows (Suzuki et al., 2012). Knockdown of
chemerin or CMKLR1 by ribonucleic acid interference
inhibits adipogenesis in human and mouse periadipo-
cytes (Goralski et al., 2007) and human bone marrow
stromal cells, which can also differentiate into adipocytes
(Muruganandan et al., 2010). Maturation of adipocytes
leads to an increase in secretion of bioactive chemerin;
therefore, adipocytes are both producing and targeted by
chemerin signaling (Goralski and Sinal, 2009).
In mouse 3T3-L1 adipocytes, chemerin potentiated
insulin-stimulated glucose uptake (Takahashi et al.,
2008), and chemerin knockdown decreased insulin-
stimulated glucose uptake (Goralski and Sinal, 2009).
In vivo, a metabolically stable analog of C9 caused a
reduction of free fatty acids in the plasma in fastedmice,
suggested to be due to the antilipolytic activity of C9
(Shimamura et al., 2009), although it could also be
through potentiation of the insulin signaling. In con-
trast, chemerin impaired insulin signaling and blocked
insulin-stimulated glucose uptake by human skeletal
muscle cells (Sell et al., 2009) and induced insulin
resistance in rat cardiomyocytes (Zhang et al., 2014).
Although it has not been explicitly stated which chem-
erin receptor is mediating the actions of chemerin in
insulin signaling and adipocyte metabolism, these
studies imply that it is through CMKLR1. However,
Goralski and Sinal, (2009) report that CMKLR1 knock-
down had no effect on insulin-stimulated glucose up-
take, and the knockout mouse studies are inconclusive
(see Section XI. A. Chemerin Receptor 1); therefore,
further study is required to identify which receptor is
mediating chemerin-induced alterations in energy
metabolism.
4. Cardiovascular System. Chemerin has been re-
ported to have roles in the human cardiovascular
system. Chemerin activation of CMKLR1 on smooth
muscle cells caused a potent contraction in vitro in
resistance vessels from humans (Kennedy et al., 2016)
and rats, but could not be replicated in mice (Watts
et al., 2013). This translated into an increase in blood
pressure in vivo in healthy rats via CMKLR1 (Kennedy
et al., 2016) and inmice (Kunimoto et al., 2015). A single
nucleotide polymorphism (SNP) in the EIDL3 gene was
found to be strongly associated with serum chemerin
levels, and this gene is known for its role in angiogenesis
(Bozaoglu et al., 2010). Subsequent in vitro studies
using human endothelial cells showed that chemerin
induced the growth of capillary-like structures in a
similar manner to vascular endothelial growth factor
(Bozaoglu et al., 2010). Also, chemerin activated key
MAPK and Akt signaling pathways and stimulated
matrix metalloproteinase gelatinolytic activity to in-
duce cell migration and angiogenesis (Kaur et al., 2010).
Although in both cases it has not been identified which
receptor is responsible for the angiogenic properties of
chemerin, Kaur et al. (2010) imply that it is via
CMKLR1 due to its expression in human endothelial
cells. Chemerin-induced angiogenesis has also been
reported in gastric cancers (Wang et al., 2014) and rat
decidua endothelial cells (Carlino et al., 2012).
B. Chemerin Receptor 2
There are currently no reported physiologic roles of
GPR1. Functional studies with receptor knockout mice
have identified potential roles in pathophysiology.
X. Pathophysiological Roles
A. Chemerin Receptor 1
1. Inflammation. Chemerin is abundant in a diverse
range of inflammatory fluids, including ascitic fluids
from ovarian or liver cancer, or ovary hyperstimulation
syndrome, as well as synovial fluids from arthritic
patients. This suggests that the chemerin/CMKLR1
system is involved in many pathologies that have a
proinflammatory element (Wittamer et al., 2003). Ret-
inoid acid–activated human endothelial cells (repre-
senting inflamed endothelial cells seen in inflammatory
diseases) promoted myeloid and plasmacytoid dendritic
cell translocation across an endothelial monolayer
through chemerin production and CMKLR1 activation
(Gonzalvo-Feo et al., 2014). This has been reported in
psoriasis (Vermi et al., 2005; Albanesi et al., 2009;
Skrzeczynska-Moncznik et al., 2009b), lupus nephritis
(De Palma et al., 2011), and multiple sclerosis (Lande
et al., 2008). Chemerin not only initiates its own
inflammatory response by recruitment of immune cells,
but can also upregulate production of other inflamma-
tory mediators via CMKLR1. One example is increased
production of interleukin-6, chemokine (C-C motif)
ligand 2, and matrix metalloproteinase 3 from
fibroblast-like synoviocytes by chemerin in rheumatoid
arthritis (Kaneko et al., 2011). Animal models using
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CMKLR1-deficient mice (see Section XI. A. Chemerin
Receptor 1) are in agreement that chemerin/CMKLR1
have a role in the modulation of inflammatory diseases,
and, similar to in vitro studies, chemerin exhibits both
pro- and anti-inflammatory responses.
2. Obesity. It has been well characterized that
circulating chemerin levels are higher in patients with
obesity (Bozaoglu et al., 2007; Sell et al., 2009; Stefanov
et al., 2014), and chemerin and CMKLR1 expression is
upregulated in adipose tissue from obese subjects
(Catalán et al., 2013). Similarly, chemerin and
CMKLR1 levels are higher in mice fed on a high-fat
diet (Roh et al., 2007) and mouse models of obesity
(Ernst et al., 2010; Parlee et al., 2010). Chemerin is well
characterized in its role in adipogenesis and energy
metabolism (see Section IX. A. 3. Adipogenesis and
Energy Metabolism), and it is through these mecha-
nisms that the link between the adipokine and obesity is
explained. Another important observation is that proin-
flammatory mediator, TNF-a, upregulated chemerin
expression in periadipocytes from humans (Catalán
et al., 2013), mice (Parlee et al., 2010), and cows
(Suzuki et al., 2012), suggesting that the chronic low
levels of inflammation seen in obesity could enhance
further the autocrine chemerin signaling. Further
discussion on this topic can be found in a review by
Roman et al. (2012).
3. Cardiovascular Disease. A novel role of chemerin
and CMKLR1 in cardiovascular disease is emerging,
both as a consequence of this signaling pathway’s
known roles in obesity/metabolic syndrome and inflam-
mation (as outlined above) as well as direct actions on
the cardiovascular system.
The implications of CMKLR1 in obesity increase the
risk of these patients developing cardiovascular dis-
ease. In addition, hypertensive patients have signifi-
cantly higher plasma concentrations of chemerin
compared with healthy controls, and levels of chemerin
positively correlate with body mass index and blood
pressure (Yang et al., 2010). The finding that chemerin
caused a significant increase in blood pressure in vivo in
normotensive rats (Kennedy et al., 2016) suggests that
in conditions such as obesity, in which chemerin levels
are chronically upregulated (Stejskal et al., 2008; Dong
et al., 2011; Lin et al., 2012; Wang et al., 2013; Stefanov
et al., 2014), this could lead to the development of
hypertension by direct activation of CMKLR1 on the
vascular smooth muscle. There has been a proposal put
forward by Ferland andWatts (2015) for a further role of
chemerin in the pathology of hypertension through its
ability to activate dendritic cells (most likely via
CMKLR1) after injury and stimulate an immune axis
of hypertension, but as yet no experimental evidence of
this.
Chemerin and its receptor could be involved in
atherosclerosis. Chemerin and CMKLR1 expression
were present in atherosclerotic plaques (Kostopoulos
et al., 2014), and aortic and coronary atherosclerosis
positively correlates with chemerin expression in the
periaortic or pericoronary adipose tissue (Spiroglou
et al., 2010). Similarly, serum chemerin levels reflect
the extent of coronary atherosclerosis in patients
(Xiaotao et al., 2012). The exact mechanisms of chem-
erin/CMKLR1 signaling in atherosclerosis have yet to
be investigated, so further research needs to be carried
out. Some ideas that are currently being considered are
that CMKLR1 could initiate the disease through vas-
cular injury, either by abnormal contractile function
(Ferland and Watts, 2015) or decreased nitric oxi-
de/cGMP signaling (Neves et al., 2014), which could be
a result of downregulation of chemerin/CMKLR1 seen
in rat endothelial cells treated with atherogenic factors
(Zhao et al., 2013). The proinflammatory nature of
chemerin could induce chemotaxis of CMKLR1-
expressing dendritic cells, macrophages, and natural
killer cells contributing to the progression of the disease
(Rhee, 2011), as could its known roles in adipogenesis
and lipid metabolism (Goralski et al., 2007) and angio-
genesis (Kaur et al., 2010).
Some studies have reported anti-inflammatory roles
of CMKLR1 that are cardioprotective. In mice, C15
treatment prior to acutemyocardial infraction inhibited
neutrophil infiltration and heart damage (Cash et al.,
2013). RvE1 blocks human vascular smooth muscle cell
migration, a pivotal stage in the onset of atherosclerosis
(Ho et al., 2010). Activation of non-neuronal muscarinic
receptor enhances chemerin/CMKLR1 signaling in a
dysfunctional endothelium to restore function (Zhao
et al., 2013).
In rat aorta, chemerin increases vascular constrictor
responses to phenylephrine and endothelin-1 (Lobato
et al., 2012), and in mouse cardiomyocytes chemerin
induced apoptosis with chemerin levels dependent on
the environment, upregulated by proinflammatory
TNF-a and downregulated by insulin (Rodríguez-
Penas et al., 2015). Again, it has yet to be determined
which receptor is mediating these effects, but they could
also be means by which chemerin/CMKLR1 contribute
to cardiovascular disease.
4. Other Roles. There are many reported single-
nucleotide variations in the human CMKLR1 gene, but
as yet only one has been associated with pathophysiol-
ogy. The SNP rs1878022 located within an intron in the
CMKLR1 gene on chromosome12q23.3 was statistically
significantly associated with decreased overall survival
in advanced stage patients with nonsmall cell lung
cancer undergoing platinum-based chemotherapy (Wu
et al., 2011). This suggests that CMKLR1 could have a
role in cancer, and in vitro studies are in agreement.
Chemerin stimulates cell invasion of human esophageal
squamous cancer cell (Kumar et al., 2016), gastric
cancer cells (Wang et al., 2014), and mesenchymal
stromal cells (Kumar et al., 2014). The unclear picture
surrounding the role of chemerin in inflammation is
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apparent in cancer as well. In mice, coculturing macro-
phages with tumor cells caused an upregulation of
CMKLR1, and, when treated with chemerin, there
was increased expression of proinflammatorymediators
(Rama et al., 2011). However, another report found that
in melanoma, chemerin inhibited tumor growth in vivo
by recruiting CMKLR1-expressing natural killer cells
(Pachynski et al., 2012).
CMKLR1 has been further implicated in other dis-
eases through limited studies. One study has shown
that CMKLR1mRNAwas upregulated in brain tissue of
patients with Alzheimer’s disease, proposing that
CMKLR1 has a role in chemotaxis of microglia cells
and uptake of inflammatory mediator Ab42 (Peng et al.,
2015). CMKLR1 was found to be essential for myogenic
differentiation in mouse C2C12 cells, and this was
consistent withCMKLR1-deficientmice having a subtle
skeletal muscle deficit (Issa et al., 2012).
B. Chemerin Receptor 2
1. Human Immunodeficiency Virus. The only
known role of human GPR1 is in human immunodefi-
ciency virus (HIV) replication. GPR1 acts as a corecep-
tor facilitating the replication of HIV-1 and HIV-2 in
brain-derived cells (Edinger et al., 1997; Shimizu et al.,
2009) and HIV/simian immunodeficiency virus in
mesangial cells of the glomerulus (Tokizawa et al.,
2000). It has also been identified as a coreceptor to
HIV strains derived from brain and blood samples from
patients with AIDS (Ohagen et al., 2003). Using the
N-terminal extracellular region of GPR1, Jinno-Oue
et al. (2005) synthesized a peptide, GPR1ntP-(1–27),
based on the N terminus of humanGPR1, that inhibited
the infection of different strains of HIV. This effect was
not specific to HIV strains that required GPR1 as a
coreceptor, and so it is believed that GPR1ntP-(1–27)
interacts directly with intact HIV virions to prevent
binding and therefore entry into host cells.
2. Other Roles. A knockout mouse study has identi-
fied that GPR1 is involved in the regulation of glucose
homeostasis (Rourke et al., 2014), suggesting that this
novel chemerin receptor could have a comparable role to
CMKLR1 in metabolic disorders (see Section X. A. 2.
Obesity).
Also in concordance with the emerging roles of
CMKLR1 in the cardiovascular system, GPR1 has been
linked to cardiovascular disease. The Medical Research
Council’s British Genetics of Hypertension study iden-
tified GPR1 as one of the candidate genes that corre-
sponded to a region of interest in the genome-wide
mapping of human loci for essential hypertension
(Caulfield et al., 2003). GPR1 mRNA was found to be
regulated during the transformation of contractile and
quiescent smooth muscle cells to the proliferative,
migratory, and synthetic state, a pivotal stage in the
onset and progression of atherosclerosis (Karagiannis
et al., 2013).
Similarly, in normal human oral keratinocytes, GPR1
mRNAwas found to be significantly upregulated during
senescence compared with the proliferating phenotype
(Kang et al., 2003), suggesting that GPR1 could play a
more general role in cell transformations.
Most recently, a novel role of GPR1 was reported in
progesterone synthesis in mice. Chemerin suppressed
progesterone production in cultured follicle and corpus
luteum and prostaglandin F2a-activated caspase-3,
resulting in a subsequent reduction in progesterone
secretion, both of which were mediated by this receptor
(Yang et al., 2016). Likewise, although the receptor(s)
responsible has yet to be identified, chemerin inhibited
production of progesterone and estrodial in human
(Reverchon et al., 2012) and rat (Wang et al., 2012)
granulosa cells and testosterone in rat testis (Li et al.,
2014b), suggesting a role for chemerin in the regulation
of gonodal steriogenesis.
The identification of these second active signaling
chemerin receptors means that it is now imperative to
pharmacologically characterize the target of novel
functions of chemerin. The current studies, which
hypothesize that the effect is through one receptor
based only on receptor distribution (at times when both
receptor distributions have not been studied), need to be
repeated in the presence of a selective antagonist to
confirm the target. Presently, there is overlap in func-
tion of GPR1 and CMKLR1 in adipogenesis and lipid
metabolism, the cardiovascular system, and reproduc-
tive biology. The contradictory literature around the
function of CMKLR1 particularly in the adipose tissue
could be due to influences of chemerin signaling at
GPR1, advocating further the need for a GPR1 antag-
onist to be developed.
XI. Genetically Modified Animals
A. Chemerin Receptor 1
Disruption of the CMKLR1 gene in mice resulted in
viable homozygous and heterozygous offspring that
displayed no differences in breeding, growth, and
survival compared with WT under physiologic condi-
tions (Graham et al., 2009; Luangsay et al., 2009).
Knockout models have exemplified the role of
CMKLR1 in inflammation and are in agreement with
the in vitro studies that chemerin through CMKLR1
has the ability to induce both pro- and anti-
inflammatory effects. Compared with WT controls,
CMKLR12/2 mice had significantly reduced clinical
signs to the dihydrotestosterone-induced polycystic
ovary syndrome (Tang et al., 2016), experimental
autoimmune encephalomyelitis (Graham et al., 2009),
and chronic obstructive pulmonary disease (Demoor
et al., 2011). TheCMKLR12/2mice were shown to have
a slower development of clinical symptoms of irritable
bowel syndrome, although ultimately developed similar
levels of inflammation and illness as WT (Dranse et al.,
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2015). CMKLR12/2 mice gave a similar inflammatory
response, with equivalent neutrophil and monocyte
recruitment to WTmice in zymosan-induced peritonitis
(Cash et al., 2008). However, CMKLR1-deficient
mice had an increased inflammatory response in
lipopolysaccharide-induced acute lung inflammation
(Luangsay et al., 2009) and had delayed clearance of
the virus and a higher mortality, in the pneumonia
virus of mice model (Bondue et al., 2011a), as a result of
the loss of the anti-inflammatory pathways involving
CMKLR1.
Chemerin has been shown to have antimicrobial
properties; chemerin-deficient mice topically infected
with Staphylococcus aureus had 10 times higher bacte-
rial levels after 24 hours compared with WT (Banas
et al., 2013). The study implies, due to an increased
expression seen in the skin, that chemerin is acting
through CMKLR1, although the exact mechanism has
not been identified.
The CMKLR1 knockout mice have highlighted the
potential role of CMKLR1 in metabolic syndrome and
obesity, although findings are not consistent. Ernst
et al. (2012) report that CMKLR12/2 mice had a lower
food consumption, leading to decreased total body mass
and percent body fat; they had reduced inflammatory
responses, including decreased TNF-a and interleukin-
6 levels in adipose tissue, decreased hepatic dendritic
cell inflammation, and increased natural killer cells in
adipose tissue, and were glucose intolerant compared
with WT mice. These observations were found whether
the mice were fed on a normal or a high-fat diet.
However, others identified that CMKLR12/2mice only
had amild tendency to obesity (Wargent et al., 2015) but
did exacerbate impaired glucose homeostasis and in-
sulin resistance (Huang et al., 2016) when fed on a high-
fat diet. In contrast, some studies describe no effect on
body weight and no difference in insulin resistance in
CMKLR12/2 mice even when fed on a high-fat diet
(Rouger et al., 2013; Gruben et al., 2014), and thus when
CMKLR1-deficient bone marrow was transplanted into
a mouse model of nonalcohol fatty liver disease (low-
density lipid receptor knockout), there was no difference
in liver pathology or insulin resistance (Gruben et al.,
2014). Although adipocyte differentiationwas unaffected
in CMKLR12/2 mice, GPD1 expression, a lipogenic
marker, was elevated, suggesting CMKLR1 could have
a role in adipocyte metabolism (Rouger et al., 2013).
CMKLR12/2 mice on a high-fat diet also had no
response when exposed to cold conditions, whereas WT
mice had a significant decrease in body mass and
improved glucose intolerance and insulin resistance,
suggesting a role of CMKLR1 in regulating thermo-
genesis (Huang et al., 2016).
B. Chemerin Receptor 2
There has currently only been one study carried out
using GPR1-deficient mice. Disruption of the GPR1
gene in mice resulted in viable homozygous and hetero-
zygous offspring that displayed no differences in breed-
ing, growth, and survival compared with WT under
physiologic conditions. However, Rourke et al. (2014)
report that when fed on a high-fat diet, GPR1 knockout
mice develop heightened glucose intolerance, compared
with WT, with no effect on body weight, percent body
fat, or energy expenditure due to consumption of
significantly less food. When tested for pyruvic acid
tolerance, GPR12/2 exhibited reduced glucose-
stimulated insulin levels, leading to an increase in
blood glucose levels. Similar to CMKLR1, this suggests
that GPR1 may also be involved in adipogenesis and
glucose homeostasis.
Although no SNPs reported in the GPR1 or CMKLR1
gene implicate them with obesity and metabolic syn-
drome, there is a positive correlation found between
common genetic variants in the RARRES2 gene (SNP
rs17173608 and rs10278590) with increased visceral
adiposity (Müssig et al., 2009). Similarly, chemerin-
deficient mice showed impaired glucose-dependent in-
sulin secretion, and chemerin transgenic mice had
improved glucose-dependent insulin secretion and glu-
cose tolerance (Takahashi et al., 2011). However, the
authors did not determine through which receptor
chemerin was functioning. A must-do study is to
knock out both GPR1 and CMKLR1 in mice to inves-
tigate whether it is through both receptors that
chemerin exerts its effects. Comparisons of responses
in double-knockout mice with chemerin-deficient and
single-receptor knockout mice would be insightful.
This strategy could be employed in areas where both
receptors appear to have similar physiology.
There are reported SNPs in the human GPR1 gene,
with one, rs16838070, shown to be associated with
increased risk of developing late-onset Alzheimer’s
disease (Chaudhry et al., 2015). It could therefore be
important to investigate a role for GPR1 in Alzheimer’s
disease, and it might be of interest to explore whether
Ab42, a proposed ligand for CMKLR1, which is crucially
involved in the pathogenesis of Alzheimer’s disease,
binds and functions through GPR1.
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